Ascend Capital’s Celgene Corp CELG Stock Holding History

Ascend Capital’s Portfolio CELG Stock Details CELG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-98,850	Closed	-$7.85M	–	243
2018 Q2	$7.85M	Sell	98,850 -225,802	-70%	-$18.7M	0.37%	94
2018 Q1	$29M	Buy	+324,652	New	+$31.2M	1.18%	25
2017 Q1	–	Sell	-27,842	Closed	-$3.22M	–	198
2016 Q4	$3.22M	Buy	+27,842	New	+$3.1M	0.16%	115
2015 Q3	–	Sell	-251,043	Closed	-$29.1M	–	192
2015 Q2	$29.1M	Buy	+251,043	New	+$28.7M	0.96%	39
2014 Q4	–	Sell	-200,772	Closed	-$19M	–	235
2014 Q3	$19M	Buy	200,772 +100,440	+100%	+$9.06M	0.56%	71
2014 Q2	$8.62M	Buy	+100,332	New	+$7.63M	0.29%	99

Other funds holding CELG

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Edgewood Management Greenwich, Connecticut $15.5B AUM 9.67% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ascend Capital's CELG Position: Q3 2018 in Review

Ascend Capital sold out of Celgene Corp (CELG) in Q3 2018, closing a stake of 98,850 shares — an estimated $7.85M sold.

Ascend Capital first reported a position in CELG in Q2 2014 and held it in 6 quarters. The position peaked at $29.1M in Q2 2015. 1,364 funds tracked by Wall St. Rank hold CELG as of Q3 2018.

Ascend Capital reported no remaining Celgene Corp position as of Q3 2018 after selling out during the quarter.
Ascend Capital sold 98,850 Celgene Corp shares in Q3 2018, an estimated $7.85M.
Ascend Capital first reported a position in Celgene Corp in Q2 2014 and held it in 6 quarters.
Ascend Capital's Celgene Corp position peaked at $29.1M in Q2 2015.
1,364 funds tracked by Wall St. Rank held Celgene Corp as of Q3 2018.

Based on Ascend Capital's 13F filing for Q3 2018, filed 13 Nov 2018.